CoChat

Safety of biologics in psoriasis

Open access
Kamata, Masahiro, Tada, Yayoi · 2018 · The Journal of Dermatology
Cited by 133

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The advent of biologics brought a paradigm shift in ways to treat psoriatic patients because they have dramatic efficacy. At the same time, safety concerns about biologics have been raised. In this paper, we focus on the safety profile of biologics for psoriasis. As of 2017, six biologics are available in Japan. Two tumor necrosis factor‐α inhibitors; infliximab and adalimumab, one anti‐interleukin (IL)‐12/23p40 antibody; ustekinumab, and IL‐17 inhibitors; secukinumab, ixekizumab and brodalumab. Secukinumab and ixekizumab are anti‐IL‐17A antibodies. Brodalumab is an anti‐IL 17 RA antibody. In this review, we pick up topics which have drawn attention regarding the safety of biologics and discuss them with recent published work.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1346-8138.14096

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 133

Metadata

Authors
Kamata, M., & Tada, Y.
Venue
The Journal of Dermatology
Publisher
Wiley
Published
2017-12-10
Volume
45
Issue
3
Pages
279-286
ISSN
  • 0385-2407 (ISSN-L)
  • 1346-8138
OpenAlex
W2772247176
Cited by
133
References
9
FWCI
2.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of biologics in psoriasis. https://app.cochat.ai/papers/10.1111/1346-8138.14096
The paper
Kamata, M., & Tada, Y. (2018). Safety of biologics in psoriasis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.14096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.